Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2001 Apr;84(7):903–909. doi: 10.1054/bjoc.2000.1706

Brain metastases at the time of presentation of non-small cell lung cancer: a multi-centric AERIO analysis of prognostic factors

W Jacot 1, X Quantin 1, J-M Boher 2, F Andre 3, L Moreau 4, M Gainet 5, A Depierre 5, E Quoix 4, T Le Chevalier 3, J-L Pujol 1,2
PMCID: PMC2363840  PMID: 11286469

Abstract

A multi-centre retrospective study involving 4 French university institutions has been conducted in order to identify routine pre-therapeutic prognostic factors of survival in patients with previously untreated non-small cell lung cancer and brain metastases at the time of presentation. A total of 231 patients were recorded regarding their clinical, radiological and biological characteristics at presentation. The accrual period was January 1991 to December 1998. Prognosis was analysed using both univariate and multivariate (Cox model) statistics. The median survival of the whole population was 28 weeks. Univariate analysis (log-rank), showed that patients affected by one of the following characteristics proved to have a shorter survival in comparison with the opposite status of each variable: male gender, age over 63 years, poor performance status, neurological symptoms, serum neuron-specific enolase (NSE) level higher than 12.5 ng ml−1, high serum alkaline phosphatase level, high serum LDH level and serum sodium level below 132 mmol l−1. In the Cox's model, the following variables were independent determinants of a poor outcome: male gender: hazard ratio (95% confidence interval): 2.29 (1.26–4.16), poor performance status: 1.73 (1.15–2.62), age: 1.02 (1.003–1.043), a high serum NSE level: 1.72 (1.11–2.68), neurological symptoms: 1.63 (1.05–2.54), and a low serum sodium level: 2.99 (1.17–7.62). Apart from 4 prognostic factors shared in common with other stage IV NSCLC patients, whatever the metastatic site (namely sex, age, gender, performance status and serum sodium level) this study discloses 2 determinants specifically resulting from brain metastasis: i.e. the presence of neurological symptoms and a high serum NSE level. The latter factor could be in relationship with the extent of normal brain tissue damage caused by the tumour as has been demonstrated after strokes. Additionally, the observation of a high NSE level as a prognostic determinant in NSCLC might reflect tumour heterogeneity and understimated neuroendocrine differentiation. © 2001 Cancer Research Campaignhttp://www.bjcancer.com

Keywords: brain metastases, non-small cell lung cancer, neuron-specific enolase, prognosis

Full Text

The Full Text of this article is available as a PDF (184.9 KB).

Footnotes

“Association d'Enseignement et de Recherche des Internes en Oncologie”(residents in oncology association for education and research), 36 rue des Vinaigriers, 75010 Paris, France, Fax 33 1 42 05 81 44

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Agboola O., Benoit B., Cross P., Da Silva V., Esche B., Lesiuk H., Gonsalves C. Prognostic factors derived from recursive partition analysis (RPA) of Radiation Therapy Oncology Group (RTOG) brain metastases trials applied to surgically resected and irradiated brain metastatic cases. Int J Radiat Oncol Biol Phys. 1998 Aug 1;42(1):155–159. doi: 10.1016/s0360-3016(98)00198-9. [DOI] [PubMed] [Google Scholar]
  2. Andersen P. K. Survival analysis 1982-1991: the second decade of the proportional hazards regression model. Stat Med. 1991 Dec;10(12):1931–1941. doi: 10.1002/sim.4780101208. [DOI] [PubMed] [Google Scholar]
  3. Ando Y., Sugiura S., Ando M., Minami H., Nomura F., Sakai S., Shimokata K. Acceptability of patients with brain metastases for clinical trials of chemotherapy for metastatic non-small-cell lung cancer. Am J Clin Oncol. 1996 Oct;19(5):478–482. doi: 10.1097/00000421-199610000-00010. [DOI] [PubMed] [Google Scholar]
  4. Auchter R. M., Lamond J. P., Alexander E., Buatti J. M., Chappell R., Friedman W. A., Kinsella T. J., Levin A. B., Noyes W. R., Schultz C. J. A multiinstitutional outcome and prognostic factor analysis of radiosurgery for resectable single brain metastasis. Int J Radiat Oncol Biol Phys. 1996 Apr 1;35(1):27–35. doi: 10.1016/s0360-3016(96)85008-5. [DOI] [PubMed] [Google Scholar]
  5. Bréchot J. M., Chevret S., Nataf J., Le Gall C., Frétault J., Rochemaure J., Chastang C. Diagnostic and prognostic value of Cyfra 21-1 compared with other tumour markers in patients with non-small cell lung cancer: a prospective study of 116 patients. Eur J Cancer. 1997 Mar;33(3):385–391. [PubMed] [Google Scholar]
  6. Büttner T., Lack B., Jäger M., Wünsche W., Kuhn W., Müller T., Przuntek H., Postert T. Serum levels of neuron-specific enolase and s-100 protein after single tonic-clonic seizures. J Neurol. 1999 Jun;246(6):459–461. doi: 10.1007/s004150050383. [DOI] [PubMed] [Google Scholar]
  7. Charloux A., Hedelin G., Dietemann A., Ifoundza T., Roeslin N., Pauli G., Quoix E. Prognostic value of histology in patients with non-small cell lung cancer. Lung Cancer. 1997 May;17(1):123–134. doi: 10.1016/s0169-5002(97)00655-7. [DOI] [PubMed] [Google Scholar]
  8. Cunningham R. T., Watt M., Winder J., McKinstry S., Lawson J. T., Johnston C. F., Hawkins S. A., Buchanan K. D. Serum neurone-specific enolase as an indicator of stroke volume. Eur J Clin Invest. 1996 Apr;26(4):298–303. doi: 10.1046/j.1365-2362.1996.129282.x. [DOI] [PubMed] [Google Scholar]
  9. Cunningham R. T., Young I. S., Winder J., O'Kane M. J., McKinstry S., Johnston C. F., Dolan O. M., Hawkins S. A., Buchanan K. D. Serum neurone specific enolase (NSE) levels as an indicator of neuronal damage in patients with cerebral infarction. Eur J Clin Invest. 1991 Oct;21(5):497–500. doi: 10.1111/j.1365-2362.1991.tb01401.x. [DOI] [PubMed] [Google Scholar]
  10. DeGiorgio C. M., Correale J. D., Gott P. S., Ginsburg D. L., Bracht K. A., Smith T., Boutros R., Loskota W. J., Rabinowicz A. L. Serum neuron-specific enolase in human status epilepticus. Neurology. 1995 Jun;45(6):1134–1137. doi: 10.1212/wnl.45.6.1134. [DOI] [PubMed] [Google Scholar]
  11. DeGiorgio C. M., Heck C. N., Rabinowicz A. L., Gott P. S., Smith T., Correale J. Serum neuron-specific enolase in the major subtypes of status epilepticus. Neurology. 1999 Mar 10;52(4):746–749. doi: 10.1212/wnl.52.4.746. [DOI] [PubMed] [Google Scholar]
  12. Diener-West M., Dobbins T. W., Phillips T. L., Nelson D. F. Identification of an optimal subgroup for treatment evaluation of patients with brain metastases using RTOG study 7916. Int J Radiat Oncol Biol Phys. 1989 Mar;16(3):669–673. doi: 10.1016/0360-3016(89)90483-5. [DOI] [PubMed] [Google Scholar]
  13. Ellis R., Gregor A. The treatment of brain metastases from lung cancer. Lung Cancer. 1998 May;20(2):81–84. doi: 10.1016/s0169-5002(98)00009-9. [DOI] [PubMed] [Google Scholar]
  14. Fogel W., Krieger D., Veith M., Adams H. P., Hund E., Storch-Hagenlocher B., Buggle F., Mathias D., Hacke W. Serum neuron-specific enolase as early predictor of outcome after cardiac arrest. Crit Care Med. 1997 Jul;25(7):1133–1138. doi: 10.1097/00003246-199707000-00012. [DOI] [PubMed] [Google Scholar]
  15. Furuse K., Fukuoka M., Kawahara M., Nishikawa H., Takada Y., Kudoh S., Katagami N., Ariyoshi Y. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol. 1999 Sep;17(9):2692–2699. doi: 10.1200/JCO.1999.17.9.2692. [DOI] [PubMed] [Google Scholar]
  16. Gaspar L., Scott C., Rotman M., Asbell S., Phillips T., Wasserman T., McKenna W. G., Byhardt R. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys. 1997 Mar 1;37(4):745–751. doi: 10.1016/s0360-3016(96)00619-0. [DOI] [PubMed] [Google Scholar]
  17. Gould V. E., Linnoila R. I., Memoli V. A., Warren W. H. Neuroendocrine components of the bronchopulmonary tract: hyperplasias, dysplasias, and neoplasms. Lab Invest. 1983 Nov;49(5):519–537. [PubMed] [Google Scholar]
  18. Harrell F. E., Jr, Lee K. L., Matchar D. B., Reichert T. A. Regression models for prognostic prediction: advantages, problems, and suggested solutions. Cancer Treat Rep. 1985 Oct;69(10):1071–1077. [PubMed] [Google Scholar]
  19. Hsiung C. Y., Leung S. W., Wang C. J., Lo S. K., Chen H. C., Sun L. M., Fang F. M. The prognostic factors of lung cancer patients with brain metastases treated with radiotherapy. J Neurooncol. 1998 Jan;36(1):71–77. doi: 10.1023/a:1005775029983. [DOI] [PubMed] [Google Scholar]
  20. Jørgensen L. G., Hansen H. H., Cooper E. H. Neuron specific enolase, carcinoembryonic antigen and lactate dehydrogenase as indicators of disease activity in small cell lung cancer. Eur J Cancer Clin Oncol. 1989 Jan;25(1):123–128. doi: 10.1016/0277-5379(89)90059-x. [DOI] [PubMed] [Google Scholar]
  21. Kelly K., Bunn P. A., Jr Is it time to reevaluate our approach to the treatment of brain metastases in patients with non-small cell lung cancer? Lung Cancer. 1998 May;20(2):85–91. doi: 10.1016/s0169-5002(98)00020-8. [DOI] [PubMed] [Google Scholar]
  22. Komaki R., Pajak T. F., Byhardt R. W., Emami B., Asbell S. O., Roach M., 3rd, Pedersen J. E., Curran W. J., Jr, Lattin P., Russell A. H. Analysis of early and late deaths on RTOG non-small cell carcinoma of the lung trials: comparison with CALGB 8433. Lung Cancer. 1993 Dec;10(3-4):189–197. doi: 10.1016/0169-5002(93)90179-2. [DOI] [PubMed] [Google Scholar]
  23. Komarnicky L. T., Phillips T. L., Martz K., Asbell S., Isaacson S., Urtasun R. A randomized phase III protocol for the evaluation of misonidazole combined with radiation in the treatment of patients with brain metastases (RTOG-7916). Int J Radiat Oncol Biol Phys. 1991 Jan;20(1):53–58. doi: 10.1016/0360-3016(91)90137-s. [DOI] [PubMed] [Google Scholar]
  24. Lagerwaard F. J., Levendag P. C., Nowak P. J., Eijkenboom W. M., Hanssens P. E., Schmitz P. I. Identification of prognostic factors in patients with brain metastases: a review of 1292 patients. Int J Radiat Oncol Biol Phys. 1999 Mar 1;43(4):795–803. doi: 10.1016/s0360-3016(98)00442-8. [DOI] [PubMed] [Google Scholar]
  25. Lonjon M., Paquis P., Michiels J. F., Frenay M., Bensadoun R. J., Chatel M., Roche J. L., Grellier P. Métastases cérébrales uniques des cancers broncho-pulmonaires. Rev Neurol (Paris) 1994;150(3):216–221. [PubMed] [Google Scholar]
  26. Martens P., Raabe A., Johnsson P. Serum S-100 and neuron-specific enolase for prediction of regaining consciousness after global cerebral ischemia. Stroke. 1998 Nov;29(11):2363–2366. doi: 10.1161/01.str.29.11.2363. [DOI] [PubMed] [Google Scholar]
  27. Merrill R. M., Henson D. E., Barnes M. Conditional survival among patients with carcinoma of the lung. Chest. 1999 Sep;116(3):697–703. doi: 10.1378/chest.116.3.697. [DOI] [PubMed] [Google Scholar]
  28. Missler U., Wiesmann M., Friedrich C., Kaps M. S-100 protein and neuron-specific enolase concentrations in blood as indicators of infarction volume and prognosis in acute ischemic stroke. Stroke. 1997 Oct;28(10):1956–1960. doi: 10.1161/01.str.28.10.1956. [DOI] [PubMed] [Google Scholar]
  29. Mountain C. F. Revisions in the International System for Staging Lung Cancer. Chest. 1997 Jun;111(6):1710–1717. doi: 10.1378/chest.111.6.1710. [DOI] [PubMed] [Google Scholar]
  30. Newman S. J., Hansen H. H. Proceedings: Frequency, diagnosis, and treatment of brain metastases in 247 consecutive patients with bronchogenic carcinoma. Cancer. 1974 Feb;33(2):492–496. doi: 10.1002/1097-0142(197402)33:2<492::aid-cncr2820330225>3.0.co;2-o. [DOI] [PubMed] [Google Scholar]
  31. Nguyen L. N., Maor M. H., Oswald M. J. Brain metastases as the only manifestation of an undetected primary tumor. Cancer. 1998 Nov 15;83(10):2181–2184. doi: 10.1002/(sici)1097-0142(19981115)83:10<2181::aid-cncr17>3.0.co;2-j. [DOI] [PubMed] [Google Scholar]
  32. Nicolson G. L. Tumor cell instability, diversification, and progression to the metastatic phenotype: from oncogene to oncofetal expression. Cancer Res. 1987 Mar 15;47(6):1473–1487. [PubMed] [Google Scholar]
  33. Nussbaum E. S., Djalilian H. R., Cho K. H., Hall W. A. Brain metastases. Histology, multiplicity, surgery, and survival. Cancer. 1996 Oct 15;78(8):1781–1788. [PubMed] [Google Scholar]
  34. Paesmans M., Sculier J. P., Libert P., Bureau G., Dabouis G., Thiriaux J., Michel J., Van Cutsem O., Sergysels R., Mommen P. Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. The European Lung Cancer Working Party. J Clin Oncol. 1995 May;13(5):1221–1230. doi: 10.1200/JCO.1995.13.5.1221. [DOI] [PubMed] [Google Scholar]
  35. Paesmans M., Sculier J. P., Libert P., Bureau G., Dabouis G., Thiriaux J., Michel J., Van Cutsem O., Sergysels R., Mommen P. Response to chemotherapy has predictive value for further survival of patients with advanced non-small cell lung cancer: 10 years experience of the European Lung Cancer Working Party. Eur J Cancer. 1997 Dec;33(14):2326–2332. doi: 10.1016/s0959-8049(97)00325-0. [DOI] [PubMed] [Google Scholar]
  36. Postmus P. E., Smit E. F. Chemotherapy for brain metastases of lung cancer: a review. Ann Oncol. 1999 Jul;10(7):753–759. doi: 10.1023/a:1008318515795. [DOI] [PubMed] [Google Scholar]
  37. Pujol J. L., Grenier J., Daurès J. P., Daver A., Pujol H., Michel F. B. Serum fragment of cytokeratin subunit 19 measured by CYFRA 21-1 immunoradiometric assay as a marker of lung cancer. Cancer Res. 1993 Jan 1;53(1):61–66. [PubMed] [Google Scholar]
  38. Radice P. A., Matthews M. J., Ihde D. C., Gazdar A. F., Carney D. N., Bunn P. A., Cohen M. H., Fossieck B. E., Makuch R. W., Minna J. D. The clinical behavior of "mixed" small cell/large cell bronchogenic carcinoma compared to "pure" small cell subtypes. Cancer. 1982 Dec 15;50(12):2894–2902. doi: 10.1002/1097-0142(19821215)50:12<2894::aid-cncr2820501232>3.0.co;2-g. [DOI] [PubMed] [Google Scholar]
  39. Ryan G. F., Ball D. L., Smith J. G. Treatment of brain metastases from primary lung cancer. Int J Radiat Oncol Biol Phys. 1995 Jan 15;31(2):273–278. doi: 10.1016/0360-3016(93)E0073-F. [DOI] [PubMed] [Google Scholar]
  40. Schoerkhuber W., Kittler H., Sterz F., Behringer W., Holzer M., Frossard M., Spitzauer S., Laggner A. N. Time course of serum neuron-specific enolase. A predictor of neurological outcome in patients resuscitated from cardiac arrest. Stroke. 1999 Aug;30(8):1598–1603. doi: 10.1161/01.str.30.8.1598. [DOI] [PubMed] [Google Scholar]
  41. Sen M., Demiral A. S., Cetingöz R., Alanyali H., Akman F., Sentürk D., Kinay M. Prognostic factors in lung cancer with brain metastasis. Radiother Oncol. 1998 Jan;46(1):33–38. doi: 10.1016/s0167-8140(97)00124-2. [DOI] [PubMed] [Google Scholar]
  42. Shepherd F. A. Chemotherapy for non-small cell lung cancer: have we reached a new plateau? Semin Oncol. 1999 Feb;26(1 Suppl 4):3–11. [PubMed] [Google Scholar]
  43. Simon R., Altman D. G. Statistical aspects of prognostic factor studies in oncology. Br J Cancer. 1994 Jun;69(6):979–985. doi: 10.1038/bjc.1994.192. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Swift P. S., Phillips T., Martz K., Wara W., Mohiuddin M., Chang C. H., Asbell S. O. CT characteristics of patients with brain metastases treated in RTOG study 79-16. Int J Radiat Oncol Biol Phys. 1993 Jan 15;25(2):209–214. doi: 10.1016/0360-3016(93)90341-r. [DOI] [PubMed] [Google Scholar]
  45. Sørensen J. B., Hansen H. H., Hansen M., Dombernowsky P. Brain metastases in adenocarcinoma of the lung: frequency, risk groups, and prognosis. J Clin Oncol. 1988 Sep;6(9):1474–1480. doi: 10.1200/JCO.1988.6.9.1474. [DOI] [PubMed] [Google Scholar]
  46. Wieskopf B., Demangeat C., Purohit A., Stenger R., Gries P., Kreisman H., Quoix E. Cyfra 21-1 as a biologic marker of non-small cell lung cancer. Evaluation of sensitivity, specificity, and prognostic role. Chest. 1995 Jul;108(1):163–169. doi: 10.1378/chest.108.1.163. [DOI] [PubMed] [Google Scholar]
  47. Wunderlich M. T., Ebert A. D., Kratz T., Goertler M., Jost S., Herrmann M. Early neurobehavioral outcome after stroke is related to release of neurobiochemical markers of brain damage. Stroke. 1999 Jun;30(6):1190–1195. doi: 10.1161/01.str.30.6.1190. [DOI] [PubMed] [Google Scholar]
  48. Yesner R., Carter D. Pathology of carcinoma of the lung. Changing patterns. Clin Chest Med. 1982 May;3(2):257–289. [PubMed] [Google Scholar]
  49. Zimm S., Wampler G. L., Stablein D., Hazra T., Young H. F. Intracerebral metastases in solid-tumor patients: natural history and results of treatment. Cancer. 1981 Jul 15;48(2):384–394. doi: 10.1002/1097-0142(19810715)48:2<384::aid-cncr2820480227>3.0.co;2-8. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES